Market capitalization | $321.91m |
Enterprise Value | $304.03m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 9.99 |
P/S ratio (TTM) P/S ratio | 10.58 |
P/B ratio (TTM) P/B ratio | 11.10 |
Revenue growth (TTM) Revenue growth | 36.34% |
Revenue (TTM) Revenue | $30.43m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a ClearPoint Neuro forecast:
3 Analysts have issued a ClearPoint Neuro forecast:
Sep '24 |
+/-
%
|
||
Revenue | 30 30 |
36%
36%
|
|
Gross Profit | 18 18 |
42%
42%
|
|
EBITDA | -17 -17 |
19%
19%
|
EBIT (Operating Income) EBIT | -19 -19 |
15%
15%
|
Net Profit | -18 -18 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.
Head office | United States |
CEO | Joseph Burnett |
Employees | 107 |
Founded | 1998 |
Website | www.clearpointneuro.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.